Patient-specific therapeutic vaccines are generated from immune cells or tumor material obtained from cancer patients. This process is resource-intensive, but has yielded therapeutic vaccines with clinical benefit. In contrast, large numbers of doses of off-the-shelf vaccines can be manufactured at one time, then stored until needed. In theory, off-the-shelf vaccines should be cheaper to manufacture while simplifying time and supply lines. Professional illustration by Alice Y. Chen.